1007 North Orange Street
4th Floor
Wilmington, DE 19802
United States
857-444-0553
https://www.ayalapharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Ruth Ben Yakar Ph.D. | Chief Exec. Officer | N/D | N/D | 1970 |
Dr. Stela Gangrenovitch Ph.D. | Co-Founder, Chief Scientist Officer and Director | N/D | N/D | N/D |
Mr. Mark Gengrinovitch LLB | Co-Founder, Chief Financial Officer and Director | N/D | N/D | N/D |
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
La calificación ISS Governance QuickScore de Ayala Pharmaceuticals, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.